Biomarkers in heart failure: the importance of inconvenient details

ESC Heart Failure

Volumn 3, Issue 1, 2016, Pages 3-10

  Miller, Wayne L ^a   Jaffe, Allan S ^a  

^a MAYO CLINIC   (United States)

Author keywords

Assessment and management; Biomarkers; Heart failure; Serial monitoring

Indexed keywords

EID: 85029756167     PISSN: None     EISSN: 20555822     Source Type: Journal    
DOI: 10.1002/ehf2.12071     Document Type: Review

References (40)

1. Elster SK, Braunwald E, Wood HF. A study of C-reactive protein in the serum of patients with congestive heart failure. Am Heart J 1956; 51: 533–541.
2. Vasan RS. Biomarkers of cardiovascular disease. Molecular basis and practical considerations. Circulation 2006; 113: 2335–2362.
3. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 1990; 263: 1385–1389.
4. Johnson RT, Dickersin K. Publication bias against negative results from clinical trials: three of the seven deadly sins. Nat Clin Pract Neurol 2007; 3: 590–591.
5. Apple FS, Collinson PO, IFCC Task Force on Clinical Applications of Cardiac Biomarkers. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012; 58: 54–61.
6. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002; 40: 976–982.
7. th percentile reference value of cardiac troponin assays. Clin Chem 2012; 58: 219–225.
8. Christ M, Laule-Kilian K, Hochholzer W, Klima T, Breidthardt T, Perruchoud AP, Mueller C. Gender-specific risk stratification with B-type natriuretic peptide levels in patients with acute dyspnea (BASAL study). J Am Coll Cardiol 2006; 48: 1808–1812.
9. Christenson RH, Azzazy HME, Duh S-H, Maynard S, Seliger SL, deFilippi CR. Impact of increased body mass index on accuracy of B-type natriuretic peptide (BNP) and N-terminal proBNP for diagnosis of decompensated heart failure and prediction of all-cause mortality. Clin Chem 2010; 56: 633–641.
10. Das SR, Abdullah SM, Leonard D, Drazner MH, Khera A, McGuidre DK, deLemos JA. Association between renal function and circulating levels of natriuretic peptides (Dallas Heart Study). Am J Cardiol 2008; 102: 1394–1398.
11. Wu AHB. Serial testing of B-type natriuretic peptide and NT-proBNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Clin Chem 2006; 152: 828–834.
12. Huelsmann M, Neubold S, Resl M, Strunk G, Brath H, Francesconi C, Adlbrecht C, Prage R, Luger A, Pacher R, Clodi M. PONTIAC (NT-proBNP selection prevention of cardiac events in a population of diabetic patients without a history of cardiac disease). J Am Coll Cardiol 2013; 62: 1365–1372.
13. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126–1130.
14. Korley FK, Jaffe AS. Preparing the United States for high-sensitivity cardiac troponin assays. J Am Coll Cardiol 2013; 61: 1753–1758.
15. Gore MO, Seliger SL, deFilippi CR, Namabi V, Christenson RH, Hashim IA, Hoogeveen RC, Ayers CR, Sun W, McGuire DK, Ballantyne CM, de Lemos JA. Age and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. J Am Coll Cardiol 2014; 63: 1441–1448.
16. Miller WL, Hartman KA, Burritt MF, Grill DE, Rodeheffer RJ, Burnett JC Jr, Jaffe AS. Serial biomarker measurements in ambulatory patients with chronic heart failure—the importance of change over time. Circulation 2007; 116: 249–257.
17. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients—the international collaborative of NT-proBNP study. Eur Heart J 2006; 27: 330–337.
18. Maron BA, Leopold JA. Aldosterone receptor antagonists. Effective but often forgotten. Circulation 2010; 121: 934–939.
19. Miller WL, Hartman KA, Grill DE, Struck J, Bergmann A, Jaffe AS. Serial measurements of mid-region-pro-ANP and C-terminal-pro-vasopressin (Copeptin) in relation to B-type natriuretic peptide and troponin T in ambulatory chronic heart failure patients—incremental prognostic value. Heart (BHJ) 2012; 98: 389–394.
20. Miller WL, Hartman KA, Burritt MF, Grill DE, Jaffe AS. Profiles of serial changes in cardiac troponin T concentrations and outcomes in ambulatory patients with chronic heart failure. J Am Coll Cardiol-Heart Failure 2009; 54: 1715–1721.
21. Miller WL, Hartman KA, Grill DE, Burnett JC, Jaffe AS. Only large reductions in natriuretic peptide concentrations (BNP and NT-proBNP) are associated with improved outcomes in ambulatory patients with chronic heart failure. Clin Chem 2009; 55: 78–84.
22. Forfia PR, Watkins SP, Rame E, Stewart KJ, Shapiro EP. Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol 2005; 45: 1667–1671.
23. Cioffi G, Tarantini L, Stefenelli C, Azzetti G, Marco R, Carlucci S, Furlanello F. Changes in plasma N-terminal proBNP levels and ventricular filling pressures during intensive unloading therapy in elderly with decompensated congestive heart failure and preserved left ventricular systolic function. J Card Fail 2006; 12: 608–615.
24. Latini R, Masson S, Wong M, Barlera S, Carretta E, Staszewsky L, Vago T, Maggioni AP, Anand IS, Tan LB, Tognoni G, Cohn JN, Val-HeFT Investigators. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med 2006; 119: 70e23–70e30.
25. Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T, Angelici L, Barlera S, Parrinello G, Maggioni AP, Tognoni G, Cohn JN, for the Val-HeFT Investigators. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007; 116: 1242–1249.
26. Miller WL, Burnett JC Jr, Hartman KA, Henle MP, Burritt MF, Jaffe AS. Lower rather than higher levels of b-type natriuretic peptides (NT-proBNP and BNP) predict short-term mortality in end-stage heart failure patients treated with nesiritide. Am J Cardiol 2005; 96: 837–841.
27. Richards AM, Troughton RW. Use of natriuretic peptides to guide and monitor heart failure therapy. Clin Chem 2012; 58: 62–71.
28. Januzzi JL, Rehman SU, Mohammed AA, Bhardwaji A, Barajas L, Barajas J, Kim H-N, Baggish AL, Weiner RB, Chen-Tournoux A, Marshall JE, Moore SA, Carlson WD, Lewis GD, Shin J, Sullivan D, Parks K, Wang TJ, Gregory SA, Uthamalingam S, Semigran MJ. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction (PROTECT). J Am Coll Cardiol 2011; 58: 1881–1889.
29. Vasile VC, Saenger AK, Kroning JM, Jaffe AS. Biological and analytical variability of a novel high-sensitivity cardiac troponin T assay. Clin Chem 2010; 56: 1086–1090.
30. Bais R. The effect of sample hemolysis on cardiac troponin I and T assays. Clin Chem 2010; 56: 1357–1359.
31. Belenky A, Smith A, Zhang B, Lin S, Despres N, Wu AHB, Bluestein BI. The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. Clin Chim Acta 2004; 340: 163–172.
32. Panteghini M, Pagani F, Yeo KT, Apple FS, Christenson RH, Dati F, Mair J, Ravkilde J, Wu AHB, on behalf of the Committee on Standardization of Markers of Cardiac Damage of the IFCC. Evaluation of the imprecision at low-range concentrations of the assays for cardiac troponin determination. Clin Chem 2004; 50: 327–332.
33. Wu AHB, Wians F, Jaffe AS. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implications on interpretation of test results. Am Heart J 2013; 665: 995–999.
34. Miller WL, Grill DE, Struck J, Jaffe AS. Association of elevated Copeptin and hyponatremia with enhanced risk in patients with chronic ambulatory heart failure. Am J Card 2013; 111: 880–85.
35. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 2009; 150: 795–802.
36. Hilden J, Gerds TA. A note on the evaluation of novel biomarkers: do not rely on IDI and NRI. Stat Med 2014; 33: 3405–3414.
37. Neeland IJ, Dranzer MH, Berry JD, Ayers CR, de Filippi C, Seliger SL, Nambi V, McGuire DK, Omland T, de Lemos JA. Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population. J Am Coll Cardiol 2013; 61: 187–195.
38. Ledwidge M, Gallagher J, Conlon C, Talon E, O'Connell E, Dawkins I, Watson C, O'Hanlon R, Bermingham M, Patle A, Badabhagni MR, Murtagh G, Boon V, Tilson L, Barry M, McDonald L, Maurer B, McDonald K. Natriuretic peptide-based screening and collaborative care of heart failure—the STOP-HF randomized trial. JAMA 2013; 310: 66–74.
39. Li X, Qi Y, Li Y, Zhang S, Guo S, Chu S, Gao P, Zhu D, Wu Z, Lu L, Shen W, Jai N, Niu W. Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction. Circ Heart Fail 2013; 6: 156–165.
40. Weir RAP, Miller AM, Murphy GEJ, Clements S, Steedman T, Connell JMC, McInnes IB, Dargie HJ, McMurray JJV. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol 2010; 55: 243–250.